Journal
ENDOCRINE-RELATED CANCER
Volume 26, Issue 8, Pages C7-C11Publisher
BIOSCIENTIFICA LTD
DOI: 10.1530/ERC-19-0186
Keywords
neuroendocrine tumours; peptide receptor radionuclide therapy; hsp90 inhibition
Categories
Ask authors/readers for more resources
Peptide receptor radionuclide therapy (PRRT) with [Lu-177]Lu-DOTA-[Tyr3] octreotate has been successfully developed in the last decades for the treatment of neuroendocrine neoplasms. However, different methods to improve the objective response rate and survival are under investigation. This includes changes of the radioligand, dosimetry and combination therapy with different agents, such as radiosensitisers. Hofving et al. recently reported, in the April 2019 issue of Endocrine-Related Cancer, the use of heat-shock protein 90 (Hsp90) modulation to augment radiation effects as a new promising target for radiosensitisation. In this commentary, new developments in the field of PRRT are discussed, placing these new findings about Hsp90 inhibitors into context.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available